Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study
Ophthalmology and Therapy · 2026-09 · 15 (9) · 3071-3088
DOI: 10.1007/s40123-026-01457-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 27.07.2026. Verfasst von Dun Jack Fu und 7 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to evaluate 12-month real-world outcomes of faricimab for polypoidal choroidal vasculopathy (PCV) in a multi-ethnic cohort .
Methods
This was a single-center retrospective cohort study of consecutive eyes with PCV diagnosed in routine care, treated with intravitreal faricimab, and with complete baseline and 12-month follow-up. One eye per patient was analyzed. Outcomes were reported for treatment-naïve and treatment-experienced eyes switched for persistent activity or limited durability. Primary endpoints were change in visual acuity (VA) and central subfield thickness (CST) at 12 months. Ethnicity-stratified outcomes were assessed secondarily.
Results
The cohort comprised 159 eyes (40 treatment-naïve, 119 treatment-experienced). In treatment-naïve eyes, mean VA improved from 61 (standard deviation [SD] 14) letters at baseline by + 6.8 letters (SD 16; P 0.05), while CST decreased significantly by − 40 µm (SD 110; P < 0.01). Eyes received a mean of 8.2 (SD 4.2) faricimab injections over 12 months. Exploratory ethnicity-stratified analyses demonstrated baseline heterogeneity across groups, with broadly favorable anatomical and functional outcomes observed across the multi-ethnic cohort, but subgroup sizes precluded comparative efficacy assessment.
Conclusions
In routine care, faricimab was associated with clinically meaningful visual improvement in treatment-naïve PCV and anatomical improvement in both treatment-naïve and -experienced eyes. Prospective studies with adequate ethnic representation are needed to validate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK.
- Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Ophthalmology, Tel Aviv Medical Center, University of Tel Aviv, Tel Aviv, Israel.
- Save Sight Institute, The University of Sydney, Sydney, NSW, Australia.
- NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK. l.faes@nhs.net.
- Eye Clinic, Cantonal Hospital Winterthur, Winterthur, Switzerland. l.faes@nhs.net.
Zitieren
APA
Fu, D. J., Riotto, E., Nicholson, L., Fasolo, S., Trivizki, O., Spooner, K., Sivaprasad, S., & Faes, L. (2026). Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study. Ophthalmology and Therapy, 15(9), 3071-3088. https://doi.org/10.1007/s40123-026-01457-3
Vancouver
Fu DJ, Riotto E, Nicholson L, Fasolo S, Trivizki O, Spooner K, et al. Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study. Ophthalmology and Therapy. 2026;15(9):3071-3088. doi:10.1007/s40123-026-01457-3
BibTeX
@article{Fu2026,
author = {Fu, Dun Jack and Riotto, Eleonora and Nicholson, Luke and Fasolo, Sandro and Trivizki, Omer and Spooner, Kimberly and Sivaprasad, Sobha and Faes, Livia},
title = {Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study},
journal = {Ophthalmology and Therapy},
year = {2026},
volume = {15},
number = {9},
pages = {3071--3088},
doi = {10.1007/s40123-026-01457-3}
}
EUVIMED